Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

(2017) Anthony B El-Khoueiry et al.   LANCET

First-in-human study of BLU-554, a potent, highly-selective FGFR4 inhibitor designed for hepatocellular carcinoma (HCC) with FGFR4 pathway activation

(2016) R. Kim et al.   EUROPEAN JOURNAL OF CANCER

ASP5878, a Novel Inhibitor of FGFR1, 2, 3, and 4, Inhibits the Growth of FGF19-Expressing Hepatocellular Carcinoma

(2016) Takashi Futami et al.   MOLECULAR CANCER THERAPEUTICS

Oncogenic mTOR signalling recruits myeloid-derived suppressor cells to promote tumour initiation

(2016) Thomas Welte et al.   NATURE CELL BIOLOGY

Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer

(2016) R. F. Sweis et al.   Cancer Immunology Research

Global cancer statistics, 2012

(2015) Lindsey A. Torre et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Genetic Landscape and Biomarkers of Hepatocellular Carcinoma

(2015) Jessica Zucman-Rossi et al.   GASTROENTEROLOGY

Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma

(2015) Victoria Tovar et al.   GUT

Fibroblast growth factor receptor 3 isoforms: Novel therapeutic targets for hepatocellular carcinoma?

(2015) Jakob Paur et al.   HEPATOLOGY

Molecular subclasses of hepatocellular carcinoma predict sensitivity to fibroblast growth factor receptor inhibition

(2015) Benjamin Schmidt et al.   INTERNATIONAL JOURNAL OF CANCER

VEGF-A modulates expression of inhibitory checkpoints on CD8+T cells in tumors

(2015) Thibault Voron et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial

(2015) Robert J Motzer et al.   LANCET ONCOLOGY

Advances in targeted therapies for hepatocellular carcinoma in the genomic era

(2015) Josep M. Llovet et al.   Nature Reviews Clinical Oncology

Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer

(2015) Martin Schlumberger et al.   NEW ENGLAND JOURNAL OF MEDICINE

First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway

(2015) M. Hagel et al.   Cancer Discovery

Genomic characterization of a large panel of patient-derived hepatocellular carcinoma xenograft tumor models for preclinical development

(2015) Qingyang Gu et al.   Oncotarget

Trans-ancestry mutational landscape of hepatocellular carcinoma genomes

(2014) Yasushi Totoki et al.   NATURE GENETICS

Establishment and Characterization of 7 Novel Hepatocellular Carcinoma Cell Lines from Patient-Derived Tumor Xenografts

(2014) Hong Xin et al.   PLoS One

Distinct Binding Mode of Multikinase Inhibitor Lenvatinib Revealed by Biochemical Characterization

(2014) Kiyoshi Okamoto et al.   ACS Medicinal Chemistry Letters

Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models

(2013) Kiyoshi Okamoto et al.   CANCER LETTERS

Expression of Fibroblast Growth Factor 19 Is Associated with Recurrence and Poor Prognosis of Hepatocellular Carcinoma

(2013) Jiyeon Hyeon et al.   DIGESTIVE DISEASES AND SCIENCES

Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma

(2012) Seiki Miura et al.   BMC CANCER

A Novel Monoclonal Antibody to Fibroblast Growth Factor 2 Effectively Inhibits Growth of Hepatocellular Carcinoma Xenografts

(2012) L. Wang et al.   MOLECULAR CANCER THERAPEUTICS

Targeting FGFR4 Inhibits Hepatocellular Carcinoma in Preclinical Mouse Models

(2012) Dorothy M. French et al.   PLoS One

Molecularly Targeted Therapy for Advanced Hepatocellular Carcinoma in 2012: Current Status and Future Perspectives

(2012) Andrew X. Zhu   SEMINARS IN ONCOLOGY

Identification of a Therapeutic Strategy Targeting Amplified FGF19 in Liver Cancer by Oncogenomic Screening

(2011) Eric T. Sawey et al.   CANCER CELL

HCC and angiogenesis: possible targets and future directions

(2011) Andrew X. Zhu et al.   Nature Reviews Clinical Oncology

Hepatocellular Carcinoma

(2011) Hashem B. El-Serag   NEW ENGLAND JOURNAL OF MEDICINE

Biochemical Characterization of TAK-593, a Novel VEGFR/PDGFR Inhibitor with a Two-Step Slow Binding Mechanism

(2010) Hidehisa Iwata et al.   BIOCHEMISTRY

Up-regulation of the fibroblast growth factor 8 subfamily in human hepatocellular carcinoma for cell survival and neoangiogenesis

(2010) Christine Gauglhofer et al.   HEPATOLOGY

Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab

(2009) Richard S Finn et al.   Expert Review of Anticancer Therapy

Vascular Changes in Hepatocellular Carcinoma

(2008) Zhen Fan Yang et al.   Anatomical Record-Advances in Integrative Anatomy and Evolutionary Biology

Multi-Kinase Inhibitor E7080 Suppresses Lymph Node and Lung Metastases of Human Mammary Breast Tumor MDA-MB-231 via Inhibition of Vascular Endothelial Growth Factor-Receptor (VEGF-R) 2 and VEGF-R3 Kinase

(2008) J. Matsui et al.   CLINICAL CANCER RESEARCH

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE